Hepatitis B virus vaccine: A potential therapeutic alternative for the treatment of warts

Nofal, Ahmad; Elsayed, Enas; Abdelshafy, Ahmed

doi:10.1016/j.jaad.2020.04.128

Cited by 4 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, complete cure of warts was achieved in 7 of 30 patients (23.3%) of the intralesional HBV vaccine group. This came in agreement with our previous study 9 that revealed a closely similar complete clearance rate (20.7%) in 6 of 29 studied patients. In spite of the small number of the patients in both studies, the closely similar low success rate points to the limited efficacy of the intralesional HBV vaccine in the treatment of common warts.…”

Section: Discussionsupporting

confidence: 93%

“…Adverse effects in both therapeutic groups were mild and transient in the form of tolerable pain, erythema, and edema at the injection site. These findings were consistent with those reported by Nofal and colleagues 9 in the previous study of intralesional HBV vaccine and with the high safety profile observed with the global IM HBV vaccination. 6…”

Section: Discussionsupporting

confidence: 93%

“…11 Based on these observations, and given the advantage of the vaccination schedule in Egypt that includes HBV vaccine, we formerly conducted the first trial on the intralesional use of this vaccine for the treatment of common warts. 9 Because of the low success rate in the previous study (20.7%), and the fact that IM administration of HBV vaccine has an excellent record of safety and immunogenicity in immunocompetent individuals, 7 we decided to compare the efficacy of IM HBV vaccine versus its intralesional injection in common warts.…”

Section: Discussionmentioning

confidence: 99%

“…8 Therefore, we previously investigated the efficacy of intralesional HBV vaccine in the treatment of common warts, but the success rate was low (20.7%). 9 Hence, we decided to evaluate and compare the efficacy and safety of intralesional versus intramuscular (IM) HBV vaccine in the treatment of multiple common warts.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Intralesional Versus Intramuscular Hepatitis B Virus Vaccine in the Treatment of Multiple Common Warts

Nofal

Elaraby

Elkholy

2022

Self Cite

View full text Add to dashboard Cite

BACKGROUNDHepatitis B virus (HBV) vaccination is associated with stimulation of humoral and cell-mediated immunity. Intralesional HBV vaccine has been recently used as an immunotherapy of common warts with relatively low success rate.AIMTo assess the efficacy and safety of intralesional versus intramuscular (IM) HBV vaccine in the treatment of multiple common warts.PATIENTS AND METHODSThe study included 60 patients with multiple common warts who were randomly assigned to 2 groups: intralesional HBV vaccine or IM HBV vaccine. In the intralesional HBV vaccine group, the vaccine was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. Intramuscular HBV vaccine group received 3 injections in the deltoid muscle at 0, 1, and 6 months.RESULTSComplete wart clearance was reported in 7 patients (23.3%) of the intralesional HBV vaccine group and 15 patients (50%) of the IM HBV vaccine group. The difference was statistically significant in favor of the IM group (p = .0479). Adverse effects were mild and insignificant in the 2 groups.CONCLUSIONHBV vaccine, particularly the IM form seems to be a promising, well-tolerated therapeutic option for the treatment of warts.LIMITATIONSShort follow-up period and small sample size.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Intralesional Versus Intramuscular Hepatitis B Virus Vaccine in the Treatment of Multiple Common Warts

Nofal

Elaraby

Elkholy

2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The exact mechanism of action is not known but the most likely mechanism is the stimulation of Th1 immune response with release of cytokines such as interleukin -2, interleukin -12 and interferon gamma. 38…”

Section: Hepatitis B Vaccine In Wartsmentioning

confidence: 99%

What is new in dermatotherapy?

Das

Toshniwal

Madke

2021

IJDVL

View full text Add to dashboard Cite

show abstract

Intralesional acyclovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a randomized controlled trial

Gharib,

Taha,

Elradi

2024

Arch Dermatol Res

View full text Add to dashboard Cite

Treating plantar warts is still a challenging problem with a long list of diverse treatment options that none of them seems to be definitive. To evaluate the effectiveness of intralesional acyclovir versus intralesional Hepatitis-B vaccine (HBV) in treatment of multiple resistant plantar warts. Forty-eight patients with resistant plantar warts completed the study with no dropouts. They were randomized into 3 groups; group(A) receiving intralesional HBV, group (B) receiving intralesional acyclovir and group (C) receiving intralesional saline as a control group over 5 biweekly sessions or until wart clearance. Clinical outcome was assessed through sequential digital lesion photographing upon each visit. Treatment related adverse reactions were recorded. 43.8%, 37.5% & 18.7% of Groups A, B &C respectively showed a complete response. pain was obvious in 100% and 56.3% of cases receiving intralesional acyclovir and HBV respectively. Up to the 6 month follow up period, none of the complete responders in all groups returned with a recurrence. Both acyclovir and HBV showed comparable efficacy and seem to be promising options for treating plantar warts being safe, affordable, and theoretically safe in immunocompromised cases.

show abstract

Hepatitis B virus vaccine: A potential therapeutic alternative for the treatment of warts

Cited by 4 publications

References 4 publications

Intralesional Versus Intramuscular Hepatitis B Virus Vaccine in the Treatment of Multiple Common Warts

Intralesional Versus Intramuscular Hepatitis B Virus Vaccine in the Treatment of Multiple Common Warts

What is new in dermatotherapy?

Intralesional acyclovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a randomized controlled trial

Contact Info

Product

Resources

About